...
首页> 外文期刊>Lung Cancer: Targets and Therapy >Astragalus-containing Chinese herbal combinations for advanced non-small-cell lung cancer: a meta-analysis of 65 clinical trials enrolling 4751 patients
【24h】

Astragalus-containing Chinese herbal combinations for advanced non-small-cell lung cancer: a meta-analysis of 65 clinical trials enrolling 4751 patients

机译:含黄芪的中草药组合治疗晚期非小细胞肺癌:纳入4751名患者的65项临床试验的荟萃分析

获取原文

摘要

Background: Non-small-cell lung cancer (NSCLC) is a leading cause of death. Interventions to reduce mortality in patients with NSCLC represent a patient-important field of research. Little is known about interventions used outside the Western world for NSCLC. One intervention widely used in Asia is astragalus-based herbal preparations.Methods: We conducted a comprehensive systematic review of all published randomized clinical trials (RCTs) evaluating astragalus-based herbal preparations in NSCLC patients. We searched independently, in duplicate, 6 English language electronic databases and 2 Chinese-language databases. We abstracted data independently, in duplicate on studies reporting of methods, survival outcomes, tumor responses, and performance score responses. We applied a random-effects meta-analysis and report outcomes as relative risks (RR) with 95% confidence intervals (CIs).Results: We included 65 RCTs enrolling 4751 patients. All trials included the herbal preparations plus platinum-based chemotherapy versus chemotherapy alone. We pooled 7 studies (n = 529) reporting on survival at 6 months and found a pooled RR of 0.54 (95% CI, 0.45 to 0.65, P ≤ 0.0001). We included 20 trials in (n = 1520) for survival at 12 months and found a pooled RR of 0.65 (95% CI, 0.54 to 0.79, P ≤ 0.0001). This effect was consistent at 24 and 36 months. When we applied a composite endpoint of any tumor treatment response we pooled data from 57 trials and found a pooled RR of 1.35 in favor of herbal treatment (95% CI, 1.26 to 1.44, P ≤ 0.0001). Statistical heterogeneity was low across trials.Limitations: The quality of reporting the RCTs was generally poor. There is also reason to believe that studies reported as randomized may not be.Conclusions: We found a large treatment effect of adding astragalus-based herbal treatment to standard chemotherapy regimens. There is a pressing need for validation of these findings in well-conducted RCTs in a Western setting.
机译:背景:非小细胞肺癌(NSCLC)是主要的死亡原因。降低NSCLC患者死亡率的干预措施是患者重要的研究领域。对于西方国家以外的非小细胞肺癌的干预措施知之甚少。在亚洲广泛使用的一种干预措施是基于黄芪的草药制剂。方法:我们对所有已发表的评估非小细胞肺癌患者基于黄芪的草药制剂的随机临床试验(RCT)进行了全面的系统评价。我们独立搜索了6个英语电子数据库和2个中文数据库。我们独立提取数据,重复研究方法,生存结果,肿瘤反应和表现评分反应的研究报告。我们进行了一项随机效应荟萃分析,并以95%的置信区间(CI)报告结果为相对风险(RR)。结果:我们纳入了65项RCT,纳入4751名患者。所有试验均包括草药制剂以及铂类化疗与单纯化疗的比较。我们汇总了7项研究(n = 529),报告了6个月的生存率,发现汇总的RR为0.54(95%CI,0.45至0.65,P≤0.0001)。我们纳入了20项(n = 1520)的12个月生存期试验,发现汇总的RR为0.65(95%CI,0.54至0.79,P≤0.0001)。在24个月和36个月时,这种效果是一致的。当我们应用任何肿瘤治疗反应的复合终点时,我们汇总了57项试验的数据,发现汇总的RR为1.35,有利于草药治疗(95%CI,1.26至1.44,P≤0.0001)。各试验之间的统计异质性较低。局限性:报告RCT的质量通常较差。结论:我们发现在标准化疗方案中添加以黄芪为基础的草药治疗具有很大的治疗效果。迫切需要在西方国家进行良好的RCT中验证这些发现。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号